Clinical Trials › NCT01892722
Active, Not RecruitingPhase 3
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Sponsored by Novartis Pharmaceuticals
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 240
Target enrollment
8
U.S. states
Jul 2013
Start date
Feb 2030
Expected completion
Interventions / Treatments
Interferon beta-1aFingolimodPlacebo capsulePlacebo i.m. injection
Conditions studied
Multiple Sclerosis
Where this trial is running (10 sites)
California2 sites
Los Angeles · San Francisco
Florida2 sites
Miami · Tallahassee
Alabama1 site
Birmingham
Massachusetts1 site
Boston
Michigan1 site
Detroit
New Jersey1 site
New Brunswick
Pennsylvania1 site
Philadelphia
Utah1 site
Salt Lake City
Participating MS centers on MS Buddy (8)
UAB Center for Pediatric Onset Demyelinating Disease
Birmingham, AL
Birmingham, AL
Robert Wood Johnson Center for MS
New Brunswick, NJ
New Brunswick, NJ
Children's Hospital of Philadelphia Pediatric MS Clinic
Philadelphia, PA
Philadelphia, PA
Children's Hospital Los Angeles Neuroimmunology Program
Los Angeles, CA
Los Angeles, CA
UCSF Multiple Sclerosis Center
San Francisco, CA
San Francisco, CA
Massachusetts General Hospital MS Clinic
Boston, MA
Boston, MA
MS centers in California
Compare treatment centers near a trial site — patient experience, providers, and care ratings.
View California centersMore Phase 3 trials
Browse all Phase 3 MS trialsCheck out the MS Buddy App
Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.
